Compare PMVP & CLST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMVP | CLST |
|---|---|---|
| Founded | 2013 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 66.9M |
| IPO Year | 2020 | 2021 |
| Metric | PMVP | CLST |
|---|---|---|
| Price | $1.63 | $16.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 815.6K | 3.4K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $10.67 |
| 52 Week High | $1.88 | $16.98 |
| Indicator | PMVP | CLST |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 57.36 |
| Support Level | $1.32 | $15.20 |
| Resistance Level | $1.86 | $16.98 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 72.67 | 45.36 |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.